Abstract

Objective To investigate the association of the modified cardiometabolic index (MCMI) with cardiovascular-kidney-metabolic (CKM) syndrome staging, all-cause and cardiovascular mortality, and compare its predictive performance with traditional indices.

Methods This prospective cohort study included 5,189 adults with CKM syndrome (stages 0–4) from NHANES 1999–2018 (median follow-up 10.4 years). Associations were assessed using polynomial/ordinal logistic regression, Cox models, and restricted cubic splines. Mediation analysis explored diabetes’ role. Competing risks (Fine-Gray), E-values, and sensitivity analyses ensured robustness. Predictive performance was compared using C-index and AUC.

Results MCMI showed a “decelerating increase” nonlinear association with CKM staging (adjusted OR=3.90, 95%CI: 3.38–4.50). For all-cause mortality, MCMI>3.5 exhibited a threshold effect (Q4 vs Q1: HR=1.412, 1.046–1.907); RCS curves identified MCMI<3.5 as a safety interval. For cardiovascular mortality, MCMI showed a fluctuating nonlinear pattern with low-risk (3.0–3.5) and high-risk (<2.5 or >4.0) intervals. Diabetes mediated 45.5% of MCMI-cardiovascular mortality risk (total HR=1.374, indirect HR=1.141). Competing risks revealed substantial underestimation of true effects (Q4 vs Q1 sHR=3.25, trend P<0.001). MCMI remained independently associated with all-cause mortality after extensive adjustments (HR=1.22, 1.05–1.40); E-values (1.73/1.29) indicated robustness. MCMI demonstrated superior predictive performance over CMI and TyG (mean AUC difference 0.0243).

Conclusions MCMI is an independent predictor of CKM progression and mortality. Its cardiovascular mortality risk is predominantly mediated by diabetes. MCMI>3.5 may serve as a clinical cut-off, outperforming traditional metabolic indices for CKM risk stratification.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

www.cdc.gov/nchs/nhanes/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

AbbreviationsAll-cause mortality Antihypertensive useAll-cause mortality Antihypertensive medication useBMIBody Mass IndexCKMCardiovascular-Kidney-Metabolic syndromeCVD deathCardiovascular disease deathHbA1cGlycated HemoglobinHDL-CHigh-Density Lipoprotein CholesterolLDL-CLow-Density Lipoprotein CholesterolMCMIModified Cardiometabolic indexmDBPMean Diastolic Blood PressureMetsMetabolic syndromemSBPMean Systolic Blood PressureSUASerum Uric AcidTCTotal CholesterolTGTriglyceridesUACRUrine Albumin-to-Creatinine RatioWCWaist Circumference